Initial Clinical Trial of Oral TAC-101, a Novel Retinoic Acid Receptor-Alpha Selective Retinoid, in Patients With Advanced Cancer

200233 citationsJournal Article

Authors

Naiyer A. Rizvi · Georgetown University

John L. Marshall · Georgetown University

Elizabeth Ness · Georgetown University

Michael Hawkins · Georgetown University

Craig M. Kessler · Georgetown University

Helena M. Jacobs · Georgetown University

Wayne D. Brenckman ·

Abstract

This is the first human clinical study with TAC-101, a RAR-alpha selective retinoid. Musculoskeletal toxicity and hypertriglyceridemia were observed characteristics of previously studied retinoids. The recommended phase II dose is 24 mg/m(2) with this treatment schedule. Alternative treatment schedules and prospective evaluation of thrombotic risk will be investigated in subsequent studies.

Topics & Keywords

Retinoids in leukemia and cellular processes Antioxidant Activity and Oxidative Stress Drug-Induced Ocular Toxicity

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 20, Issue 16, pp. 3522-3532

DOI: 10.1200/jco.2002.02.090

Field-Weighted Citation Impact: 1.22